The emerging role of the transient receptor potential cation channel isotype 6 (TRPC6) as a central contributor to various pathological processes affecting podocytes has generated interest in the development of therapeutics to modulate its function. Recent insights into the regulation of TRPC6 have revealed PKG as a potent negative modulator of TRPC6 conductance and associated signaling via its phosphorylation at two highly conserved amino acid residues: dephosphorylation and also inhibited TRPC6-dependent podocyte motility by 30 -60%. These data reveal that PKG activation strategies, including PDE5 inhibition, ameliorate ANG II-induced podocyte dysmotility by targeting TRPC6 in podocytes, highlighting the potential therapeutic utility of these approaches to treat hyperactive TRPC6-dependent glomerular disease.
calcineurin; phosphodiesterase 5; podocyte; protein kinase G; transient receptor potential cation channel isotype 6 TRANSIENT RECEPTOR POTENTIAL cation channel isotype 6 (TRPC6) is a Ca 2ϩ -permeable, nonselective cation channel widely recognized as a central contributor to several forms of glomerular disease, including focal segmental glomerulosclerosis, minimal change nephropathy, membranous nephropathy, and diabetic nephropathy (28, 42, 45) . In addition to the evolving role of TRPC6 in kidney disease, aberrant activity of this ion channel has been implicated in the pathogenesis of cardiac hypertrophy, pulmonary vascular hypertension, cancer, and diabetes (6, 12, 33, 47) . Consequently, TRPC6 has become a focus of considerable interest as a potentially valuable therapeutic target (6, 44) . Unfortunately, efforts to develop selective inhibitors of TRPC6 have been hindered by limited specificity, potency, or in vivo efficacy (37) .
The recent identification of PKG as a potent negative regulator of TRPC6 activity via direct phosphorylation of specific serine and threonine residues has spawned new interest in PKG agonists for the treatment of various TRPC6-associated pathologies (19, 26, 31, 36, 39, 46) . PKG is a widely expressed member of the PKA/PKG/PKC group of serine/threonine kinases. PKG regulates a diversity of intracellular processes, including cellular contractility and relaxation, regulation of cell-to-extracellular matrix attachment, directional guidance of neuronal axon extension, spermatozoa metabolism, platelet activation, and cell division (13, 24) . PKG activity is upregulated by the cyclic nucleotide second messenger cGMP. Binding of cGMP to the PKG regulatory domain induces a conformational change to activate the kinase (4, 24) . Intracellular cGMP levels are tightly regulated via the opposing activities of two enzyme classes, guanylate cyclases (GCs) that catalyze the conversion of GTP into cGMP and phosphodiesterases (PDEs) that hydrolyze cGMP to GMP (4, 24) . There are two cyclases, soluble GC (sGC) activated by nitric oxide (NO) and natriuretic receptor-associated GC (4, 35) . Their synthesis of cGMP is counterbalanced by select members of the PDE superfamily, notably PDE5, which is expressed in a tissue-restricted fashion (3, 10, 11) .
TRPC6 activation is coupled to the activation of calcineurin (Cn) phosphatase (also known as protein phosphatase 2B), a Ca 2ϩ /calmodulin-dependent serine/threonine phosphatase primarily recognized for its role in the activation of the nuclear factor of activated T cells (NFAT) signaling pathway. Cn also regulates TRPC6 gene expression in a positive feedback loop by activating NFAT-dependent TRPC6 gene transcription (20) . In addition to this role, Cn can also function as a direct modulator of TRPC6 activity via dephosphorylation of AGC kinase target residues (17) . Importantly, PKG activation strategies in heart muscle have been shown to suppress Cn-NFAT-coupled TRPC6 upregulation and associated signaling by phosphorylation of the TRPC6 channel (19) .
Here, we investigated the role of the NO/sGC/cGMP/PKG/ PDE5 signaling pathway and Cn in the regulation of TRPC6 phosphorylation in podocytes. We hypothesized that PKG negatively regulates podocyte motility via its phosphorylation of TRPC6 at Thr 69 (Thr 70 in humans) and that PDE5 inhibition ameliorates ANG II-induced podocyte dysmotility through this pathway. We revealed that TRPC6 is phosphorylated at Thr 69 in unstimulated mouse podocytes and that ANG II stimulation and Cn induce TRPC6 dephosphorylation at Thr 69 and enhance podocyte motility. Both pharmacological and genetic agonists of PKG signaling promoted TRPC6 phosphorylation and attenuated ANG II-induced podocyte dysmotility. Taken together, these results support a role for NO/sGC/cGMP/PKG/ PDE5 signaling in the regulation of TRPC6 phosphorylation in podocytes and demonstrate the potential therapeutic utility of PKG enhancement strategies to treat hyper-TRPC6 activityinduced renal disease.
METHODS
Murine podocyte culture and reagents. Conditionally immortalized murine podoctyes were cultured under growth-permissive conditions at 33°C in RPMI 1640 (GIBCO, Gaithersburg, MD) supplemented with 10% FBS (Gibco), 1:100 penicillin-streptomycin (Invitrogen, Grand Island, NY), and 10 U/ml recombinant mouse interferon-␥ (Sigma, St. Louis, MO). Podocyte differentiation was induced by transfer of cultures to growth-restrictive conditions at 37°C in interferon-␥-free media for 10 days before experimental use. Differentiated podocytes were then pretreated as indicated for 1 h before stimulation with 5 M ANG II for 24 h (Sigma).
Primary podocyte culture. Primary podocyte culture was performed using established methods (7) . Briefly, wild-type (WT) 129/SvEv mice were euthanized, and their kidneys were harvested under sterile conditions. Decapsulated glomeruli were isolated from gently ground kidneys of individual mice by a sequential wash with ice-cold PBS through 180-, 100-, and 71-m sieves (Retsch, Newtown, PA). The fraction collected on the 71-m sieve was placed on ice, and an aliquot was examined under the microscope to ensure the solution contained mainly glomeruli. After a wash in ice-cold PBS, the glomerulus-concentrated pellet was resuspended in RPMI 1640 (Sigma) supplemented with 10% FBS and 1:100 penicillin-streptomycin (Invitrogen) and cultured in a collagen type I flask (BD Biosciences, San Jose, CA) in a 37°C incubator with 5% CO2 for 3-5 days. Flasks containing the glomeruli were undisturbed until sufficient growth was noted around attached glomeruli. Old media containing unattached glomeruli were replaced with fresh media to facilitate growth toward confluence. Products were isolated by passing trypsinized outgrowing cells from the glomeruli through a 40-m nylon cell strainer (Fisher Scientific, Norcross, GA) and then cultured in RPMI 1640-supplemented medium in a collagen type I flask. Podocytes were split upon reaching 95% confluence. The validation of the exclusive presence of podocytes was routinely confirmed by standard fluorescence immunohistochemistry approaches using Wilm's tumor-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). RT-PCR was done to exclude other glomerular compartment cells such as mesangial (Thy-1) and endothelial cells (TIE-1). Additional podocyte markers were used as well to confirm the cell type, such as podocin, nephrin, and synaptopodin. Podocytes showed classical cobblestoning and arborized cell shape as well as intermediate features between these two types, depending on the passage number. Experiments were conducted within the first two to four passages of the podocyte subculture that were arborized.
Immunoblot analysis. After treatment, immortalized murine podocyte cultures were washed once with ice-cold PBS. Cells were then harvested in loading buffer (Cell Signaling Technologies, Boston, MA) supplemented with 1 M calyculin A (EMD Chemicals, Billerica, MA) and protease inhibitor cocktail at 1:400 dilution (Sigma). Whole cell extracts were then passed through a 1-ml syringe (BD Biosciences) 10 times. Cell lysates were then subjected to SDS-PAGE using NuPAGE 10% bis-Tris precast gels (Invitrogen) followed by transfer to 0.2-m pore size polyvinylidene difluoride membranes (Millipore, Billerica, MA). Membranes were blocked with a 1-h incubation in 5% milk in PBS. Protein immunoblot analysis was then performed using rabbit polyclonal anti-TRPC6 antibody (Abcam, Cambridge, MA), rabbit polycolonal anti-phospho-TRPC6 [pTRPC6 (Thr 69 )] antibody commercially generated by Biomatik (Wilmington, DE) using the published sequence reported by Nishida et al. (11) , and rabbit anti-␤-actin antibody (Cell Signaling Technologies). Membranes were then washed once with PBS and incubated for 1 h with horseradish peroxidase-conjugated goat anti-rabbit polyclonal secondary antibody at 1:10,000 dilution (Invitrogen). Immunolabled proteins were detected using a chemiluminescence detection system (Pierce Biotechnology, Rockford, IL) on Kodak Biomax film (VWR Scientific, Radnor, PA).
Scratch wound healing assay and reagents. Immortalized podocyte cultures were pretreated with S-nitroso-N-acetyl-DL-penicillamine
propoxy]ethyl-1H-imidazole hydrochloride (SKF-96365; 10 M) (EMD Biochemicals) as indicated 1 h before ANG II (Sigma) stimulation and scratch wound creation. Cell monolayers were then washed once with supplemented RPMI 1640 maintenance media. Scratch wounds were applied using 1,000-l plastic pipette tips. Podocytes were then washed once again before treatment. Podocytes were then imaged using an EVOS microscope at time 0 immediately after wound creation. Cells were then returned to growth-restrictive conditions for 24 h before final images of wound healing were obtained. Data are expressed as "percent wound healing," which represents the percent difference in wound area after 24 h.
Plasmid vector construction. Yellow fluorescent protein-tagged human (h)TRPC6 construct was kindly provided by Dr. Craig Montell (21) . PCR-based site-directed mutagenesis (Quikchange, Stratagene) was performed to introduce point mutations leading to amino acid substitutions. The mutagenic primers used for PKG phosphorylation sites have been previously reported (19) . To generate hTRPC6P112Q, following primers were used: sense 5=-GAATATGGTAACATC-CAAGTGGTGCGGAAGATG-3= and antisense 5=-CATCTTCCGC-ACCACTTGGATGTTACCATATTC-3=. Mutations were confirmed by sequencing using an Applied Biosystems 3730xl DNA Analyzer.
Adenoviral transfection. Recombinant adenoviral constructs were prepared as previously described (19) . Immortalized podocyte cultures were washed with 1ϫ RPMI 1640 before transfection with recombinant adenoviral constructs as indicated. Transfected podocytes were then subjected to a scratch wound healing assay and immunoblot analyses as previously described. Recombinant gene expression was verified by immunoblot analysis relative to endogenous ␤-actin expression.
Human embryonic kidney-293 experiments. Human embryonic kidney (HEK)-293 cells were transfected with 1 g of both ANG II type 1 receptor and WT TRPC6 or gain-of-function mutant (TRPC6P112Q) (45) as well as triple mutant with P112Q combined with phosphomimetic mutations (T70E, S322E) via plasmids using Xfect (Clontech) reagent according to the manufacturer's protocol. Each form was tagged by yellow fluorescent protein in the COOH-terminus to confirm expression. The bath solution was 140 mM NaCl, 5 mM CsCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose with pH 7.4. Stimulating conditions were created by adding ANG II (200 nM) and/or 8-pCPTcGMP (1 mM) to the bath solution. Borosilicate glass capillary pipettes (World Precision Instruments) were used with ϳ3-M⍀ resistance when filled with solution containing 5 mM NaCl, 40 mM CsCl2, 80 mM Cs-glutamate, 5 mM Mg-ATP, 5 mM EGTA, and 1.5 CaCl2 (free Ca 2ϩ concentration was 100 nM). Currents were obtained using a voltage step-pulse protocol from Ϫ100 to ϩ100 mV applied every 2 s for 500 ms from a holding potential of Ϫ60 mV. Current recordings were in a whole cell configuration using an Axopatch 200Ba amplifier (Axon Instruments).
Additional experiments were performed in HEK-293 cells transfected with pgGL4.30-NFAT firefly luciferase (NFAT-Luc) or pGL4.75-CMV Renilla luciferase (CMV-Luc, control) and PKG. Transfected cells were then stimulated with ANG II (10 nM) with or without 8-pCPT-cGMP (1 mM) for 6 h. Cells were then lysed in buffer (Promega), and NFAT-luciferase activity was determined by a Dual Luciferase Reporter Assay (Promega).
Statistical methods. All data are presented as means Ϯ SE. Group differences were assessed by t-test. Statistical significance was established at P Ͻ 0.05. For electrophysiological analyses, data are presented as mean data points with error bars as SEs. Data were analyzed by one-way ANOVA or two-way ANOVA with a Tukey post hoc test.
RESULTS

PKG activation blocks Ca
2ϩ current and NFAT activation by hTRPC6 P112Q in HEK-293 cells. HEK-293 cells do not normally express TRPC6, and patch-clamp analysis of currentvoltage dependence showed a linear relation with low conductance unaltered by administration of ANG II or 8Br-cGMP, whereas cells transfected with WT TRPC6 displayed a strong nonlinear current-voltage dependence characteristic of TRPC6 (Fig. 1A) . In a previous study (19) , we showed that cGMP blocks WT TRPC6 current with or without concomitant ANG II stimulation. Here, we show that current from a gain-offunction TRPC6 mutation associated with familial glomerulosclerosis (hTRPC6 P112Q ) (45) is suppressed by coincubation with cGMP both with or without ANG II stimulation (Fig. 1, B and C). Combining the P112Q hyperfunction mutation with phosphomimetic mutations simulating PKG phosphorylation (hTRPC6 P112Q/T70E/S322E ) (19) reduced channel conductance and blocked its ANG II activation (Fig. 1, D and E) . We next tested if the hTRPC6 P112Q mutant enhanced NFAT activation and if this too was suppressed by PKG. Basal NFAT activation was markedly augmented by the mutation and blunted by cGMP incubation. Expression of the hTRPC6 P112Q/T70E/S322E form displayed similarly reduced NFAT activity with or without cGMP, confirming that the Thr 70 and Ser 322 residues were PKG targets (Fig. 1F) . Thus, PKG agonism abrogated the enhanced Ca 2ϩ conductance of the TRPC6 P112Q mutant by a mechanism mimicked by pseudophosphorylation at PKG target residues.
TRPC6 is phosphorylated at Thr 69 in vivo and in vitro. Next, we examined if TRPC6 is normally phosphorylated at Thr 69 in mouse podocytes using custom-generated polyclonal pTRPC6 (Thr 69 ) antibody. In Fig. 2A, ) was detected in the whole kidney and primary podocytes from WT mice but not in tissue from TRPC6 knockout (KO) mice (Fig. 2B) (7) . Interestingly, ANG II stimulation resulted in time-dependent Thr 69 dephosphorylation in primary mouse podocytes (Fig. 2C) , which, based on the data shown in Fig. 1 , is consistent with enhanced channel TRPC6 conductance.
Functional effect of a phosphomimetic TRPC6 mutant on ANG II-induced podocyte motility. ANG II is a potent inducer of podocyte cytoskeletal injury whose deleterious effects are mediated via aberrant TRPC6 activation (14) . Based on previous studies from our laboratory, we posited that ANG II induces podocyte dysfunction through dysregulation of TRPC6-mediated podocyte motility (1, 2, 5, 16, 25, 34) . To test this, we used the scratch wound healing assay technique to assess podocyte migration in response to ANG II stimulation (27) . Primary and conditionally immortalized podocytes were stimulated with ANG II, ) antibody detected pTRPC6 in the whole kidney and mouse primary podocyte lysates. Whole kidney protein extract (left) and primary podocyte cell lysates (right) from WT and TRPC6-deficient knockout (KO) mice were stained for pTRPC6, TRPC6, and ␤-Actin. C: time course of TRPC6 dephosphorylation in response to chronic ANG II stimulation. ANG II dephosphorylation occurred within 6 h of the initiation of ANG II treatment. and motility, expressed as percent wound healing, was quantified after 24 h. First, we evaluated ANG II-induced motility in WT and TRPC6 KO primary podocytes stimulated with ANG II. ANG II-induced podocyte motility increased almost 20% relative to nonstimulated WT primary podocytes. In KO podocytes, basal and ANG II-induced motility were significantly reduced; however, the phenotype was rescued in KO podocytes expressing WT hTRPC6 (Ad-TRPC6 WT ). Thus, ANG II-induced podocyte motility is TRPC6 dependent. Next, podocytes overexpressing Ad-TRPC6 WT , phospho-null TRPC6 (Ad-TRPC6 T70A/S322Q ), or phospho-mimetic TRPC6 (Ad-TRPC6 T70E/S322E ) were stimulated with ANG II. In Ad-TRPC6 WT -overexpressing cells, ANG II significantly induced podocyte motility by 24% relative to unstimulated cells ( Fig. 3A; summary data in Fig. 3B ). In Ad-TRPC6 T70A/ S322Q-overexpressing podocytes, basal motility increased 16% above nonstimulated cells, supporting that in the absence of TRPC6 phosphorylation at these residues, basal motility was enhanced, highlighting their importance to TRPC6-dependent podocyte motility. Conversely, in Ad-TRPC6 T70E/S322E -overexpressing podocytes, ANG II-induced podocyte motility was attenuated Ͼ20% relative to TRPC6 WT and TRPC6 T70A/S322Q .
Enhanced PKG expression and/or activation augments TRPC6 Thr 69 phosphorylation and attenuates ANG II-induced podocyte migration. To examine the role of PKG in the phosphorylation of TRPC6 in podocytes, cells were infected with recombinant adenovirus expressing hPKG, and podocyte motility and Thr 69 phosphorylation were assessed in the presence of ANG II stimulation. PKG overexpression attenuated podocyte motility relative to control green fluorescent protein-overexpressing cells, and this effect was amplified by coincubation with 8Br-cGMP or a PDE5 inhibitor (Fig.  4, A and B) .
We next assessed the impact of PKG pathway activation on ANG II-induced podocyte motility. Increased podocyte motility (ϩ40% relative to unstimlated controls) by ANG II was significantly attenuated by Ͼ35% from exposure to the TRPC6 antagonist SKF-96356. Similar suppression was attained by coexposure to the NO donor SNAP, 8Br-cGMP, the sGC activator Bay 41-2272, and PDE5i (Fig. 5, A and B) . PKG activation also offset ANG II-induced dephosphorylation of Fig. 3 . TRPC6 KO attenuates ANG II-induced podocyte motility. A: representative images of scratch wound healing assays in WT and TRPC6 KO primary podocytes. Basal and ANG II-induced podocyte motility were significantly reduced in KO podocytes relative to WT primary podocytes. This phenotype was rescued in KO podocytes expressing hTRPC6WT. B: quantitation of KO wound healing assays. Data are expressed as means Ϯ SE for 6 experiments. Overexpression of phosphomimetic TRPC6 attenuated ANG II-induced podocyte migration. C: representative images of scratch wound healing assays in Ad-hTRPC6WT-, Ad-hTRPC6T70A/S322Q-, or Ad-hTRPC6T70E/S322E-overexpressing podocytes stimulated with ANG II. D: basal and ANG II-induced podocyte migration were significantly attenuated in podocytes overexpressing hTRPC6T70E/S322E relative to podocytes overexpressing hTRPC6WT or hTRPC6T70E/S322Q (n ϭ 6). Data are expressed as means Ϯ SE for 6 experiments. TRPC6 (Fig. 5C ). Taken together, these data show ANG II to be a potent activator of TRPC6-dependent podocyte motility that results in the dephosphorylation of TRPC6. Both effects are attenuated by PKG activation, with inhibitors of PDE5 being the most effective.
Constitutively active Cn dephosphorylates TRPC6 at Thr
69
and stimulates cell motility. Since TRPC6 channel conductance is coupled to the activation of the phosphatase Cn, we assessed the effects of expressing constitutively active Cn (CA-Cn) on podocyte motility and TRPC6 phosphorylation. Basal motility in CA-Cn-overexpressing cells was increased 20% over control cells (Fig. 6, A and B) and accompanied by reduced phosphoThr 69 TRPC6 (Fig. 6, C and D) . This is consistent with a regulatory role of Cn-dependent signaling both on dephosphorylation and thus stimulation of TRPC6 channel conductance and associated podocyte migration.
DISCUSSION
Historically, the role of the NO/sGC/cGMP/PKG/PDE5 signaling pathway in podocytes has been overlooked due to uncertainties of the cell source of NO and inconsistent detection of other components of this pathway. However, vascular endothelial cells have now been identified as a primary source of NO production, which plays an important paracrine role in glomerular function. For example, Kanetsuna et al. (15) reported that endothelial NO synthase (eNOS)-deficient (eNOS Ϫ/Ϫ ) C57B/6 mice develop pronounced foot process effacement, proteinuria, and glomerular basement membrane thickening in response to streptozotocin-induced diabetes, whereas their eNOS ϩ/ϩ littermates do not. eNOS Ϫ/Ϫ C57B/6 mice are also more susceptible to podocyte injury and dysfunction in the same diabetic model (48) . These data support the importance of vascular endothelial cell-derived NO to podocyte communication in maintaining podocyte structural and functional integrity. With respect to downstream NO signaling in podocytes, the sGC ␤-subunit has been detected by RT-PCR in individually microdissected renal tublular segments along the rat glomerulus (41) , whereas the sGC ␣-subunit has been shown in rat glomerular podocytes by immunohistochemistry (29) . In 2006, Lewko et al. (23) reported the detection of SNAP-inducible cGMP production in cultured podocytes. Recently, Fang and colleagues (8) showed that the PDE5-selective inhibitor vardenafil ameliorates proteinuria and podocyte injury, reducing transforming growth factor-␤ and desmin expression, via its potentiation of cGMP production. Still, these studies did not define a specific role of this signaling cascade in podocytes. The present data address this, by revealing that PKG activation via a variety of methods significantly ameliorates ANG II-induced podocyte dysmotility through a mechanism involving TRPC6.
PKG phosphorylation of TRPC6 was first described in HEK-293 cells and vascular myocytes by Takahashi et al. (39) . In this study, TRPC6 channel activity was inhibited by activation of PKG by SNAP or 8Br-cGMP, and the effect was abrogated in channels with mutated PKG sites (alanine substitutions). In 2010, both Koitabashi et al. (19) 
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2ϩ conductance and was attenuated by selective inhibitors of PKG. In podocytes, we demonstrate that Thr 69 phosphorylation is similarly inhibited under identical conditions of PKG inhibition, and TRPC6-dependent podocyte motility is impaired when PKG is activated. These data demonstrate the important role of PKG-mediated phosphorylation on the modulation of podocyte TRPC6 activity in vitro. Furthermore, our findings suggest a significant role for PKG activation in the modulation of aberrant TRPC6 activity. While previous studies in the vasculature and cardiac muscle have focused on PKG suppression of excessive WT TRPC6-dependent pathophysiology, the present data show that PKG can also suppress a site-mutated gain-of-function of TRPC6 known to be relevant to glomerular disease. As hyperactive TRPC6 mutations have been increasingly linked to such disorders, these results have potential translational importance.
In 2002, two groups identified a role for ANG II in the activation of Cn signaling. Lea et al. (22) demonstrated in proximal tube epithelia that ANG II stimulation increased Cn activity. The NFAT-dependent transcriptional response to ANG II was blocked by Cn inhibitors in vascular myocytes (38) , and, in cardiomyocytes, Kuwahara et al. (20) revealed a positive feedback loop by which TRPC6-mediated Ca 2ϩ influx activated Cn-NFAT signaling, which, in turn, increased transcription of the channel. A similarly functional feedback loop has been since described in podocytes (30) . Importantly, studies in cardiac myocytes have shown that PKG activation can disrupt this feedback loop, reducing both NFAT activation (dephosphorylation) and TRPC6 expression (18, 19, 31) . Here, we add another previously unidentified component of this feedback, namely, that sustained ANG II stimulation also leads to reduced phosphorylation of TRPC6 at Thr 69 by Cn. Based on present and previous data, this increases TRPC6 conductance, and thus signaling, contribute to podocyte dysmotility. Notably, there is precedent for Cn as a TRPC6 phosphatase, as Cn has been shown to dephosphorylate Ser 768 in the TRPC6A isoform and Ser 714 in the TRPC6B isoform in neuronal PC12D cells (17) . Phosphorylation of these residues, like that of Thr 69 , led to reduced TRPC6 activity, which was, in turn, attenuated by Cn-mediated dephosphorylation. Cn also dephosphorylates synaptopodin at a PKA target site to promote actin cytoskeletal reorganization and thus a motile phenotype in podocytes (9) and the L-type Ca 2ϩ channel via dephosphorylation of a PKC target residue in L6 myocytes (43) . These effects, including the suppression of a TRPC6-NFAT cascade, may underlie the antiproteinuric benefits of Cn inhibitors in the treatment of some nephrotic syndromes (9, 49) but also suggest that effective PKG activation may achieve similar effects. Figure 7 shows the signaling and positive and negative controls on the TRPC6-Cn signaling cascade and its regulation by PKG in the podocyte.
In summary, we have shown a new role for PKG pathway activation and Cn in the modulation of TRPC6 activity in podocytes. The development of targeted TRPC6 antagonists continues, but, to date, agents that can be used in vivo remain lacking (37) . However, PKG activation strategies have been developed and are in clinical use for other disease conditions such as heart failure, pulmonary hypertension, and erectile dysfunction. The present findings suggest that effective activation of PKG signaling may prove beneficial as a therapeutic intervention in various TRPC6-associated podocytopathies.
